Table 1 The B16F10 mutanome

From: Translation of genomics-guided RNA-based personalised cancer vaccines: towards the bedside

Mutation selection steps for proof-of-concept

Predicted mutations a

NGS exon profiling (exomes)

12 842

High confidence somatic mutations (FDR<0.05)

3570

Mutations in transcripts

1392

Non-synonymous mutations

962

 Mutations in KEGG melanoma pathwayb

13

Mutations in expressed genes

563

Mutated peptides predicted to bind MHCc

462

Mutations selected for further analysis

50

Mutations independently confirmed as somatic

All 50 tested

Mutations tested for immunisation

50

Immunogenic mutations (ELISPOT readout)

16 (32%)

Mutation-specific immunogenicity

11 (22%)

  1. Abbreviations: FDR=false discovery rate; MHC=major histocompatibility complex.
  2. aNumbers represent subsets of the preceding values unless otherwise indicated.
  3. bKEGG pathway hsa05218 (Kanehisa and Goto, 2000).
  4. cAs predicted by the IEDB MHC-binding prediction tool (consensus score<5) (Lundegaard et al, 2008).
Back to article page